Journal
BRITISH JOURNAL OF DERMATOLOGY
Volume 177, Issue 5, Pages 1316-1321Publisher
WILEY
DOI: 10.1111/bjd.15641
Keywords
-
Categories
Funding
- Agency for Healthcare Research and Quality (AHRQ) [K12 HS023011]
- Dermatology Foundation
Ask authors/readers for more resources
Background Scoring systems for assessing the signs of atopic dermatitis (AD) are complex and difficult to interpret. Severity strata are helpful to interpret these assessments properly. Objectives To confirm previously reported strata for the Eczema Area and Severity Index (EASI), Scoring Atopic Dermatitis (SCORAD) and the objective component of SCORAD (oSCORAD), and to develop strata for the modified EASI (mEASI), Atopic Dermatitis Severity Index (ADSI) and body surface area (BSA) for use in adults with AD. Methods Skin examination was performed in 673 adolescents and adults (age = 13 years) with diagnosed AD, in a dermatology practice setting. Strata were selected using an anchoring approach based on a four-point Investigator's Global Assessment of severity (clear of active skin lesions, mild, moderate or severe disease). Results We determined potential severity strata for EASI (0 clear, 0.1-5.9 mild, 6.022.9 moderate, 23.0-72 severe; j = 0.69), mEASI (0-0.9 clear, 1-8.9 mild, 9.029.9 moderate, 30.0-90 severe; j = 0.71), oSCORAD (0-7.9 clear, 8.0-23.9 mild, 24.0-37.9 moderate, 38.0-83 severe; j = 0.70), SCORAD (0-9.9 clear, 10.0-28.9 mild, 29.0-48.9 moderate, 49.0-103 severe; j = 0.68), ADSI (0-1.9 clear, 2-5.9 mild, 6.0-8.9 moderate, 9.0-15 severe; j = 0.55) and BSA (0 clear, 0.1-15.9 mild, 16.0-39.9 moderate, 40.0-100 severe; j = 0.66). oSCORAD values > 0 were found in clear skin due to the presence of xerosis, which is scored in oSCORAD. Similarly, SCORAD values > 0 were found in clear skin due to the scoring of xerosis, pruritus and sleeplessness. Similarly, mEASI and ADSI scores > 0 occurred in patients with clear skin due to scoring of pruritus. Conclusions We recommend using these strata for interpretation of their respective measures in clinical trials of AD. There are important differences between the five assessments, which profoundly impact the interpretation of their scores.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available